Quick Answer AbCellera Biologics Inc. reported Total Revenue of $75.13 million for fiscal year 2025. AbCellera Biologics Inc. Total Revenue — Annual History Fiscal Year Total Revenue YoY Change 2025 $75.13M +160.6% 2024 $28.83M -24.2% 2023 $38.02M -92.2% 2022 $485.42M +29.4% 2021 $375.20M +60.9% 2020 $233.16M +1907.9% 2019 $11.61M — Quarterly Total Revenue Quarter Ending … Read more
Quick Answer Ameris Bancorp reported Stockholders Equity of $4.08 billion for fiscal year 2025. Ameris Bancorp Stockholders Equity — Annual History Fiscal Year Stockholders Equity YoY Change 2025 $4.08B +8.6% 2024 $3.75B +9.5% 2023 $3.43B +7.2% 2022 $3.20B +7.8% 2021 $2.97B +12.1% 2020 $2.65B +7.2% 2019 $2.47B +69.6% 2018 $1.46B +81.0% 2017 $804.48M +24.4% 2016 … Read more
Quick Answer Ameris Bancorp reported Total Assets of $27.52 billion for fiscal year 2025. Ameris Bancorp Total Assets — Annual History Fiscal Year Total Assets YoY Change 2025 $27.52B +4.8% 2024 $26.26B +4.2% 2023 $25.20B +0.6% 2022 $25.05B +5.0% 2021 $23.86B +16.7% 2020 $20.44B +12.0% 2019 $18.24B +59.4% 2018 $11.44B +45.7% 2017 $7.86B +14.0% 2016 … Read more
Quick Answer Ameris Bancorp reported Diluted EPS of $6.00 per share for fiscal year 2025. Ameris Bancorp Diluted EPS — Annual History Fiscal Year Diluted EPS YoY Change 2025 $6.00 +15.6% 2024 $5.19 +33.4% 2023 $3.89 -22.0% 2022 $4.99 -7.6% 2021 $5.40 +43.2% 2020 $3.77 +37.1% 2019 $2.75 -1.8% 2018 $2.80 +41.4% 2017 $1.98 -4.8% … Read more
Quick Answer Ameris Bancorp reported Net Income of $412.15 million for fiscal year 2025. Ameris Bancorp Net Income — Annual History Fiscal Year Net Income YoY Change 2025 $412.15M +14.9% 2024 $358.69M +33.3% 2023 $269.11M -22.3% 2022 $346.54M -8.1% 2021 $376.91M +43.9% 2020 $261.99M +62.3% 2019 $161.44M +33.4% 2018 $121.03M +64.6% 2017 $73.55M +2.0% 2016 … Read more
Quick Answer Ameris Bancorp reported Net Income of $412.15 million for fiscal year 2025. Ameris Bancorp — Key Financials by Year Metric 2025 2024 2023 2022 2021 2020 Net Income $412.15M+14.9% $358.69M+33.3% $269.11M-22.3% $346.54M-8.1% $376.91M+43.9% $261.99M+62.3% Diluted EPS $6.00+15.6% $5.19+33.4% $3.89-22.0% $4.99-7.6% $5.40+43.2% $3.77+37.1% Total Assets $27.52B+4.8% $26.26B+4.2% $25.20B+0.6% $25.05B+5.0% $23.86B+16.7% $20.44B+12.0% Stockholders Equity $4.08B+8.6% … Read more
Quick Answer AbbVie Inc. reported Operating Income of $15.07 billion for fiscal year 2025. AbbVie Inc. Operating Income — Annual History Fiscal Year Operating Income YoY Change 2025 $15.07B +65.0% 2024 $9.14B -28.4% 2023 $12.76B -29.6% 2022 $18.12B +1.1% 2021 $17.92B +57.7% 2020 $11.36B -12.5% 2019 $12.98B +103.4% 2018 $6.38B -33.1% 2017 $9.54B +2.2% 2016 … Read more
Quick Answer AbbVie Inc. reported Stockholders Equity of -$3.27 billion for fiscal year 2025. AbbVie Inc. Stockholders Equity — Annual History Fiscal Year Stockholders Equity YoY Change 2025 -$3.27B -198.3% 2024 $3.33B -67.9% 2023 $10.36B -40.0% 2022 $17.25B +12.0% 2021 $15.41B +17.8% 2020 $13.08B +260.0% 2019 -$8.17B +3.2% 2018 -$8.45B -265.7% 2017 $5.10B +9.9% 2016 … Read more
Quick Answer AbbVie Inc. reported Total Assets of $133.96 billion for fiscal year 2025. AbbVie Inc. Total Assets — Annual History Fiscal Year Total Assets YoY Change 2025 $133.96B -0.9% 2024 $135.16B +0.3% 2023 $134.71B -2.9% 2022 $138.81B -5.3% 2021 $146.53B -2.7% 2020 $150.56B +69.0% 2019 $89.11B +50.1% 2018 $59.35B -16.2% 2017 $70.79B +7.1% 2016 … Read more
Quick Answer AbbVie Inc. reported Cash and Equivalents of $5.23 billion for fiscal year 2025. AbbVie Inc. Cash and Equivalents — Annual History Fiscal Year Cash and Equivalents YoY Change 2025 $5.23B -5.3% 2024 $5.52B -56.9% 2023 $12.81B +39.3% 2022 $9.20B -5.6% 2021 $9.75B +15.4% 2020 $8.45B -78.8% 2019 $39.92B +447.7% 2018 $7.29B -21.6% 2017 … Read more